Abstract: Many patients with neurodegenerative diseases, such as Alzheimer’s (AD) and Parkinson’s (PD) diseases suffer from disease progression without any satisfying clinical intervention, likely due to our lack of knowledge on how normal aging impacts the pathogenic mechanisms of these debilitating diseases. A growing body of literature has emerged in recent years that clearly demonstrates the involvement of glycolipids in the protein-oligomerization of neurodegenerative disorders. We hypothesize that changes in glycolipids composition are a common mechanism underlying the shift from healthy brain aging to the neuropathological processes of neurodegenerative diseases.